XML 38 R37.htm IDEA: XBRL DOCUMENT v3.20.1
DESCRIPTION OF BUSINESS (Details)
$ in Thousands, shares in Millions
1 Months Ended 12 Months Ended
Sep. 30, 2016
USD ($)
shares
Dec. 31, 2019
USD ($)
segment
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Variable Interest Entity [Line Items]        
Number of operating segments | segment   1    
Cash and cash equivalents   $ 48,121 $ 50,422  
Net working capital   45,900    
Accumulated deficit   293,524 186,024  
Negative cash flows from operating activities incurred   $ 37,521 $ 22,829 $ 17,765
Viventia Bio Inc.        
Variable Interest Entity [Line Items]        
Shares of common stock issued to the selling shareholders (in shares) | shares 4.0      
Percentage of voting interests acquired (as a percent) 19.90%      
Period during which quarterly earn-outs are payable after date of net sales 15 years      
Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations 7 years      
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone        
Variable Interest Entity [Line Items]        
Percentage of net sales of quarterly earn-out payments during earn-out periods 2.00%      
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | United States        
Variable Interest Entity [Line Items]        
One-time milestone payment upon first sale of product $ 12,500      
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Europe        
Variable Interest Entity [Line Items]        
One-time milestone payment upon first sale of product 7,000      
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Japan        
Variable Interest Entity [Line Items]        
One-time milestone payment upon first sale of product $ 3,000